Surrozen Inc (SRZN) - Total Liabilities
Based on the latest financial reports, Surrozen Inc (SRZN) has total liabilities worth $334.27 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Surrozen Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Surrozen Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Surrozen Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Surrozen Inc.
Surrozen Inc Competitors by Total Liabilities
The table below lists competitors of Surrozen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Security National Financial
NASDAQ:SNFCA
|
USA | $1.18 Billion |
|
Yuan Jen Enterprises Co Ltd
TW:1725
|
Taiwan | NT$2.58 Billion |
|
Genomictree Inc.
KQ:228760
|
Korea | ₩5.45 Billion |
|
TMC Life Sciences Bhd
KLSE:0101
|
Malaysia | RM247.86 Million |
|
Hillgrove Resources Ltd
AU:HGO
|
Australia | AU$52.83 Million |
|
Autosports Group Ltd
AU:ASG
|
Australia | AU$1.53 Billion |
|
Landmark Bancorp Inc
NASDAQ:LARK
|
USA | $1.44 Billion |
|
United Bankers Oyj
HE:UNITED
|
Finland | €38.51 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Surrozen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Surrozen Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Surrozen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Surrozen Inc (2019–2025)
The table below shows the annual total liabilities of Surrozen Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $286.49 Million | +310.17% |
| 2024-12-31 | $69.85 Million | +757.54% |
| 2023-12-31 | $8.14 Million | -39.37% |
| 2022-12-31 | $13.43 Million | -51.10% |
| 2021-12-31 | $27.47 Million | +86.05% |
| 2020-12-31 | $14.77 Million | +12.73% |
| 2019-12-31 | $13.10 Million | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more